Corcept Therapeutics (CORT)
(Real Time Quote from BATS)
$25.49 USD
+0.17 (0.67%)
Updated Mar 28, 2024 01:14 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
Corcept Therapeutics Incorporated [CORT]
Reports for Purchase
Showing records 1 - 20 ( 214 total )
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Promising Data Indicate an Expanding Market; PT Up to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Remain Bullish on Cushing Syndrome Franchise; Lowering PT to $28; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CORT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Multiple Clinical Data Readouts Expected in 2024; PT Up To $34; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Company: Corcept Therapeutics Incorporated
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department